Bookmark and Share

Olga S. Latinovic

Olga S. Latinovic Ph.D., MSc

Academic Title: Assistant Professor
Primary Appointment: Microbiology and Immunology
Location: Institute of Human Virology, N 615
Phone: (410) 706-2769
Fax: (410) 706-1992

Personal History:

  • 2006: PhD, Lehigh University, PA.
  • 2006-2007: Postdoctoral Fellow, Institute of Human Virology, University of Maryland Biotechnology Institute.
  • 2007-2008: Research Associate, Institute of Human Virology, University of Maryland Biotechnology Institute.
  • 2008-2010: Research Associate, Institute of Human Virology, University of Maryland School of Medicine.
  • 2010-present: Assistant Professor, Institute of Human Virology, University of Maryland School of Medicine, Department for Microbiology and Immunology.

Research Interests:

  • HIV-1 Entry Inhibition



Olga Latinovic, Micromechanics and Structure of Soft and Biological Materials: An Optical Tweezers Study, Verlag Dr. Muller Publishing, ISBN (978-3-639-23050-5), 2010.

Ming-Tzo Wei, O. Latinovic, L. A. Hough, Y.-Q. Chen, H. D. Ou-Yang, A. Chiou, "Studying microrheology of soft and living materials using optical trapping," in Handbook of Photonics for Biomedical Engineering, Kim, Donghyun; Ho, Aaron H.-P.; Somekh, Michael G. (Eds.), Springer-Verlag, Berlin, (2014). ISBN 978-94-007-5053-1.

Recent Publications

A. Heredia, B. Gilliam, O. Latinovic, N. Le, D. Bamba, A. DeVico, G.B. Melikian, R. C. Gallo and R. R. Redfield, Rapamycin reduces CCR5 density levels on CD4 T cells and this effect results in potentiation of Enfuvirtide (T-20) against R5 HIV-1 in vitro, Antimicrobial Agents and Chemotherapy, Volume 51, No.7, 2489-2496 (2007).

A. Heredia, O. Latinovic, R. C. Gallo, G. B. Melikian, M. Reitz, N. Le and R. R. Redfield, Low doses of Rapamycin enhance the antiviral activity of CCR5 antagonist VCV against wild-type and drug resistant R5 HIV-1, Proceeding of the National Academy of Sciences, Volume 105, No. 51, 20476-20481 (2008).

K. Miyauchi, Y. Kim, O. Latinovic, V. Morozov and G. B. Melikian, HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes, Cell, Volume 137, Issue 3, 433-444 (2009).

O. Latinovic, A. Heredia, Robert C. Gallo, Marv Reitz, Nhut Le and Robert R. Redfield, Low doses of the immunomodulatory drug Rapamycin decrease the anti-HIV effective dose of the CCR5 antagonist Aplaviroc: potential clinical implications, Antiviral Research, Volume 83, 86-89 (2009).

O. Latinovic, J. Kuruppu, C. Davis, N. Lee and A. Heredia, Pharmacotherapy of HIV-1 Infection: Focus on CCR5 antagonist Maraviroc, Review for Clinical Medicine: Therapeutics, Volume 1, 1497-1510 (2009).

O. Latinovic, L. A. Hough and H. D. Ou-Yang, Structural and Micromechanical Properties of Collagen Type I, the Journal of Biomechanics, Volume 43, Issue 3, 500-505 (2010).

O. Latinovic, M. Reitz, N. Le, J. S. Foulke, G. Fatkenheuer, C. Lehmann, H. Valdez, R. R. Redfield and A. Heredia, CCR5 antibodies HGS004 and HGS101 inhibit Maraviroc-resistant HIV-1 and Inhibition is more potent in the presence of Maraviroc: Clinical Implications, Virology, (2011).

N. Jha, O. Latinovic, E. Martin, G. Novitskiy, M, Marin, K. Miyauchi, J. Naughton, J. A. T. Young and G.B. Melikyan, Imaging single retrovirus entry through alternative receptor isoforms and intermediate virus-cell fusion, PloS Pathogens, Volume 7, Issue 1, 1001260 (2011).

O. Latinovic, N. Le, M. Reitz, R. Pal, A. DeVico, J. S. Foulke, R. R. Redfield and A. Heredia, Synergistic Inhibition of CCR5-tropic HIV-1 by Maraviroc and CCR5 Antibody HGS004 in Primary Cells: Potential Implications for Treatment and Prevention, AIDS, 1;25(9):1232-5 (2011).

F. Cocchi, A. L. DeVico, W. Lu, M. Popovic, O. Latinovic, M. M. Sajadi, R. R. Redfield, M. K. Lafferty, M. Galli, A. Garzino-Demo and R. C. Gallo, The Soluble Factors from T Cells Inhibiting X4 Strains of HIV are a Mixture of Beta Chemokines and RNases, Proceeding of the National Academy of Sciences, PMID: 22431590, (2012).

O. Latinovic, K. Schneider, H. Szmacinski, J. R. Lakowicz, A. Heredia and R. R. Redfield, Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc, Antiviral Research, Volume 112: 80-90 (2014).

F. Obata, P. B. Subrahmanyam, A. E. Vozenilek, L. M. Hippler, T. Jeffers, M. Tongsuk, I. Tiper, P. Saha, D. M. Jandhyala,G. L. Kolling, O. Latinovic and T. J. Webb, Natural Killer T (NKT) cells accelerate Shiga toxin type 2 (Stx2) pathology in mice, Frontiers in Microbiology, section Infectious Diseases, doi: 10.3389/fmicb.2015.00262, (2015).

O. Latinovic, S. Medina-Moreno, K. Schneider, N. Gohain, J. Zapata, M. Pazgier, M. Reitz, J. Bryant, R.R. Redfield, Full length single chain Fc protein (FLSC IgG1) as a potent anti-viral therapy candidate: Implications for in vivo studies, AIDS Research and Human Retroviruses - Volume 31, Number 00, (2015).

F. Obata, L. M. Hippler, P. Saha, D. M. Jandhyala  and O. Latinovic, Shiga toxin type-2 (Stx2) induces glutamate release via phosphoinositide 3-kinase (PI3K) pathway in murine neurons, Frontiers of Molecular Neuroscience, ISSN: 1662-5099 (2015).

D. Basta, O. Latinovic, M. K. Lafferty, L. Sun, J. Bryant, A. Caruso, R. Gallo, A. Garzino-Demo. Angiogenic, lymphoangiogenic and adipogenic effects of HIV-1 Matrix protein p17 Ugandan variant. Pathogens and Diseases (2015). DOI:

O. Latinovic and R.R. Redfield, CCR5-Cellular doorway for HIV-1 Entry. Review for Journal for Human Virology and Retrovirology. 2(5):00056, (2015).

A. Heredia, O.S. Latinovic, F. Barbault, E. P. H. deLeeuw. A Novel Small Molecule Inhibitor of HIV Entry. Drug Design. Development and Therapy. Vol 9, 1-10 (2015).

O.S. Latinovic, J. Zhang, Y. Tagaya, A. L. DeVico, T. Fouts, K. Schneider, J. Lakowicz, A. Heredia and R. R. Redfield, Synergistic inhibition of R5 HIV-1 by Maraviroc and FLSC IgG in primary cells: Implications for prevention and treatment- Current HIV Research, PMID: 26354735, Vol 14, Issue 1, (2016).